Home/Products /paclitaxel-ip-6mg-polyoxyl-35-castor-oil-ip-527mg-dehydrtes-alcohol-ip-49-7-v-v-300mg-injection

Packlin 300 injection: Paclitaxel 6 mg/mL - Institutional Chemotherapy

Name: Packlin 300 : Paclitaxel Injection 6 mg/ml
Brand: Packlin 300 injection
Rating: 4.8 (150 reviews)

Microtubule Stabilization: The Anti-Cancer Mechanism of Paclitaxel (Taxane)

Primary Indication: First-line and Adjuvant Therapy for Breast and Ovarian Cancer

Expanding Applications: Non-Small Cell Lung Cancer (NSCLC) and Kaposi's Sarcoma

Important: Specialized Administration and Pre-medication Protocol

Secure Your Monopoly: Packlin 300 PCD Pharma Franchise in High-Volume Injectable Oncology

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Paclitaxel 6 mg/mL injection vial for chemotherapy

IV infusion setup for Ovarian Cancer chemotherapy

Oncology PCD Pharma franchise marketing visual for injectable Paclitaxel

Packlin 300 injection (Paclitaxel) Administration and Stability Protocol PDF

Packlin 300 injection

Composition : Paclitaxel IP 6mg + Polyoxyl 35 Castor oil IP 527mg + Dehydrtes Alcohol IP 49.7% v/v Injection

Dosage Form : Injection

Packaging Type : Vial

Packaging : 300mg

Price : ₹0/-

Please Contact For Best Price

Packlin 300 injection is a high-potency, intravenous chemotherapy solution containing Paclitaxel , an essential drug in the Taxane class. It is a mainstay of chemotherapy regimens worldwide for treating some of the most prevalent and aggressive cancers.

Mechanism and Impact:Paclitaxel is a cytotoxic agent that promotes the assembly of microtubules from tubulin dimers and stabilizes them, inhibiting their normal depolymerization. This action prevents the necessary restructuring of the microtubule network required for cell division, thereby leading to the arrest of mitosis and the eventual death of rapidly dividing cancer cells.

Key Therapeutic Uses:

Breast Cancer: Used in adjuvant, neoadjuvant, and metastatic settings.
Ovarian Cancer: Standard treatment for advanced ovarian carcinoma.
Non-Small Cell Lung Cancer (NSCLC): Used in combination regimens.
Kaposi's Sarcoma: For advanced cases unresponsive to prior therapy.

We offer an exclusive PCD Pharma Franchise opportunity for Packlin 300 injection, enabling partners to secure a dominant position in the highly reliable injectable oncology market.

About the Product

Key Therapeutic Uses:

Breast Cancer: Used in adjuvant, neoadjuvant, and metastatic settings.
Ovarian Cancer: Standard treatment for advanced ovarian carcinoma.
Non-Small Cell Lung Cancer (NSCLC): Used in combination regimens.
Kaposi's Sarcoma: For advanced cases unresponsive to prior therapy.

We offer an exclusive PCD Pharma Franchise opportunity for Packlin 300 injection, enabling partners to secure a dominant position in the highly reliable injectable oncology market.

Hair loss (alopecia) Nausea, vomiting, diarrhea Low blood counts (anemia, leukopenia) Peripheral neuropathy (tingling or numbness) Joint/muscle pain

Metastatic breast cancer Advanced ovarian carcinoma Non-small cell lung cancer (NSCLC) AIDS-related Kaposi’s sarcoma Often used as first-line or second-line therapy, either alone or in combination with other chemotherapeutic agents like cisplatin.

Administered intravenously by trained professionals in a clinical setting. Premedication with corticosteroids, antihistamines, and H2 antagonists is essential to minimize hypersensitivity reactions. Requires close monitoring of blood counts, liver function, and cardiac status.

Store below 25°C, protected from light. Do not freeze. Shake well before use. Keep out of reach of children.